Peptide GPCR Access BioAscent has recently partnered with Keltic Pharma to provide peptide discovery platforms for GPCR targets in Scotland, presenting a sales opportunity to offer peptide discovery capabilities and GPCR-focused screening to biopharma customers seeking target-specific peptide approaches.

University Collaboration A collaboration with the University of Edinburgh on novel MASH treatments highlights BioAscent’s open research partnerships and translational capabilities, suggesting a path to co-development programs or sponsored research with pharma and academic clients seeking innovative treatment modalities.

Expanded Facilities The new protein production facility in Newhouse strengthens BioAscent’s integrated drug discovery stack, enabling in-house bioprocessing support for target proteins and assay development, which can be pitched to sponsors needing end-to-end production-ready workflows.

Comprehensive Library BioAscent already manages over 1.5 million compounds and provides compound management, HTS, medicinal and synthetic chemistry, and in silico services, making it a one-stop partner for customers requiring robust library access and integrated screening campaigns.

Regional Footprint With its Scotland-based site and recent partnerships, BioAscent is well positioned to target European biotech and pharma companies seeking local discovery capabilities, offering fast collaboration cycles, proximity advantages, and potential co-funding or regional grant opportunities.